The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

About Mercachem-Syncom

Mercachem-Syncom provides high-quality chemistry services for clients who require a small-molecule solutions. It offers its services in four specialized business areas: discovery chemistry, medicinal chemistry, parallel chemistry, and process research and development.

Mercachem-Syncom Headquarter Location

Kerkenbos 1013

Nijmegen, 6546,


+31 0243723300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Mercachem-Syncom News

Gilde, PGGM buy Mercachem-Syncom

Aug 29, 2017

CEE M&A and Private Equity Forum 2017 unquote" and Mergermarket have joined forces to bring you a guided tour through each stage of the capital life-cycle at the CEE M&A & Private Equity Forum. Our combined expertise in upcoming M&A situations and private equity coverage promises to deliver our most in-depth analysis of the CEE region. Date: 26 Sep 2017

  • Where is Mercachem-Syncom's headquarters?

    Mercachem-Syncom's headquarters is located at Kerkenbos 1013, Nijmegen.

  • What is Mercachem-Syncom's latest funding round?

    Mercachem-Syncom's latest funding round is Acquired.

  • Who are the investors of Mercachem-Syncom?

    Investors of Mercachem-Syncom include Gilde Healthcare Partners and PGGM.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.